Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Scleroderma, Diffuse

• Platform Clinical Study for Conquering Scleroderma
• A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
• Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
• Subcutaneous Semaglutide in Systemic Scleroderma
• RY_SW01 Cell Injection Therapy in Systemic Sclerosis
• Hyaluronidase Via LADD Scleroderma-induced Microstomia
• Rituxmab Versus IL-6 in Treating ILD
• Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
• Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
• Clinical Study of Divozilimab in Patients With Systemic Scleroderma
• An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
• A Study in People With Systemic Sclerosis to Test Whether BI 685509 Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
• Effectiveness of Cannabinoids on Appetite in Scleroderma
• Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
• A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
• Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
• An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
• Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
• Phase 3 Study of MT-0551 in Patients With Systemic Sclerosis
• Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
• Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
• Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis
• Study of ACE-1334 to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease
• Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
• A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
• A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
• Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
• Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis
• A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
• A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
• A Study of Guselkumab in Participants With Systemic Sclerosis
• Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
• Effects of FT011 in Systemic Sclerosis
• Iguratimod in Systemic Sclerosis
• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
• Cold Challenge With C21 in RP
• Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis
• TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
• A Study of KHK4827 in Patients With Systemic Sclerosis
• Subcutaneous Injections of Autologous ASC to Heal Digital Ulcers in Patients With Scleroderma.
• Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
• A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
• Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma
• Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
• The Benefit of Bermekimab in Patients With Systemic Sclerosis
• Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
• A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
• A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
• KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
• Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
• Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
• Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
• A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
• Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients
• A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
• CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
• Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
• Prednisolone in Early Diffuse Systemic Sclerosis
• Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis
• A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
• Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
• Cardiac Safe Transplants for Systemic Sclerosis
• Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
• Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
• Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
• Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
• Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases
• A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis
• Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
• Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
• Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
• Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
• Intraoperative ICG for Systemic Sclerosis
• Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study
• The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
• Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
• Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis
• Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
• Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
• Riociguat in Scleroderma Associated Digital Ulcers
• Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
• SCLERoderma et Adipose-DErived Stroma Cells
• Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers
• Abituzumab in SSc-ILD
• Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
• Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
• Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
• A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
• Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
• CSL Behring Sclero XIII
• Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
• Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
• The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis
• Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
• A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
• Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
• A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects
• Exparel as a Nerve Block for Severe Hand Pain
• Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
• Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
• Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)
• Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
• Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
• Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
• Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
• Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
• Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
• Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma
• Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
• A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
• Zibotentan Better Renal Scleroderma Outcome Study
• Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
• Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
• Gastroesophageal Reflux Treatment in Scleroderma
• Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
• Rituximab in Systemic Sclerosis
• Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
• Proof of Biological Activity of SAR100842 in Systemic Sclerosis
• Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
• Serial Night Time Position Splint on Systemic Sclerosis
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
• Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study
• A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
• Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
• IL1-TRAP, Rilonacept, in Systemic Sclerosis
• A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
• Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis
• An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
• Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
• Scleroderma Treatment With Autologous Transplant (STAT) Study
• Bosentan in Systemic Sclerosis
• Post Marketing Surveillance Study of Cuprimine
• Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
• Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
• Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
• Fresolimumab In Systemic Sclerosis
• GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
• Effect of Bosentan in Scleroderma Renal Crisis
• Nilotinib in the Treatment of Systemic Sclerosis
• A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
• Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
• Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
• Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
• A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
• Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
• A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
• Early Therapy of Pulmonary Arterial Hypertension
• Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
• SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
• Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
• Open-Label Study of Oral Treprostinil in Digital Ulcers
• Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
• AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
• Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
• Effectiveness and Safety of Lidocaine for Scleroderma
• A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
• Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction
• Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
• Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
• Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
• Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis
• Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
• Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
• Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
• QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
• A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
• Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis
• Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
• Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
• A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
• Imatinib in Systemic Sclerosis
• High Dose Cyclophosphamide for Treatment of Scleroderma
• A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
• Efficacy and Safety of Imatinib in Scleroderma
• Platelet Gel in Systemic Sclerosis
• A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
• Mycophenolate Mofetil in Systemic Sclerosis
• High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
• Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
• A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
• Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
• Placebo Controlled Trial of Bosentan in Scleroderma Patients
• Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
• Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
• Bosentan in Digital Ulcers
• Open-label Study With Bosentan in Interstitial Lung Disease
• Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
• Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
• Rapamycin vs Methotrexate in Diffuse SSc
• Treatment of Early Systemic Sclerosis by Bosentan
• Imiquimod in Children With Plaque Morphea
• Scleroderma: Cyclophosphamide or Transplantation
• Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma
• Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
• Stem Cell Transplant to Treat Patients With Systemic Sclerosis
• Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
• Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
• Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
• Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
• Oral Type I Collagen for Relieving Scleroderma
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
• Scleroderma Lung Disease
• Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis